Research programme: HER2 inhibitors - Avantogen Oncology

Drug Profile

Research programme: HER2 inhibitors - Avantogen Oncology

Alternative Names: BIO 106

Latest Information Update: 16 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avantogen Oncology
  • Class
  • Mechanism of Action ERBB 2 receptor antagonists; Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 01 Jun 2006 Innovate Oncology is now a wholly owned subsidiary of Avantogen
  • 30 May 2006 Innovate Oncology has been acquired by Avantogen
  • 16 Sep 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top